title: [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1].
authors.affiliation: Medizinische Klinik II, Klinikum Grosshadern Ludwig-Maximilians-Universität Marchioninistr. 15, 81377 München. bgoeke@med2.med.uni-muenchen.de
authors.forename: Burkhard
authors.initials: B
authors.lastname: Göke
authors.forename: Bernhard
authors.initials: B
authors.lastname: Hoppe
authors.forename: Astrid
authors.initials: A
authors.lastname: Konrad
authors.forename: Jörg
authors.initials: J
authors.lastname: Schirra
mesh_terms: D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005934:Glucagon / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000502:physiology; D010446:Peptide Fragments / Q000627:therapeutic use*; D011498:Protein Precursors / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D010446:Peptide Fragments; D011498:Protein Precursors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon
vernacular_title: Eine therapeutische Option bei Typ-2-Diabetes? Das Inkretinhormon GLP-1.